KR20230084177A - 결핵균 추출물의 신규 용도 - Google Patents

결핵균 추출물의 신규 용도 Download PDF

Info

Publication number
KR20230084177A
KR20230084177A KR1020237012326A KR20237012326A KR20230084177A KR 20230084177 A KR20230084177 A KR 20230084177A KR 1020237012326 A KR1020237012326 A KR 1020237012326A KR 20237012326 A KR20237012326 A KR 20237012326A KR 20230084177 A KR20230084177 A KR 20230084177A
Authority
KR
South Korea
Prior art keywords
cancer
cells
immune adjuvant
extract
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237012326A
Other languages
English (en)
Korean (ko)
Inventor
타카유키 호리이
타카오 타나카
Original Assignee
제리아 신야쿠 고교 가부시키 가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제리아 신야쿠 고교 가부시키 가이샤 filed Critical 제리아 신야쿠 고교 가부시키 가이샤
Publication of KR20230084177A publication Critical patent/KR20230084177A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020237012326A 2020-10-09 2021-10-08 결핵균 추출물의 신규 용도 Pending KR20230084177A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2020171491 2020-10-09
JPJP-P-2020-171491 2020-10-09
JPJP-P-2020-217698 2020-12-25
JP2020217698 2020-12-25
PCT/JP2021/037410 WO2022075458A1 (ja) 2020-10-09 2021-10-08 結核菌抽出物の新規用途

Publications (1)

Publication Number Publication Date
KR20230084177A true KR20230084177A (ko) 2023-06-12

Family

ID=81126102

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237012326A Pending KR20230084177A (ko) 2020-10-09 2021-10-08 결핵균 추출물의 신규 용도

Country Status (12)

Country Link
US (1) US20230372476A1 (https=)
EP (1) EP4226939A4 (https=)
JP (1) JPWO2022075458A1 (https=)
KR (1) KR20230084177A (https=)
CN (1) CN116322771A (https=)
AU (1) AU2021357131A1 (https=)
BR (1) BR112023006220A2 (https=)
CA (1) CA3194869A1 (https=)
MX (1) MX2023004103A (https=)
TW (1) TW202228739A (https=)
WO (1) WO2022075458A1 (https=)
ZA (1) ZA202304219B (https=)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS568320A (en) * 1979-07-04 1981-01-28 Chisato Maruyama Drug for tumor immunotherapy comprising lipopolysaccharide as active constituent
JPS5632489A (en) * 1979-08-28 1981-04-01 Mitsui Toatsu Chem Inc Antitumor active substance and its pharmaceutical
JPH0680574A (ja) * 1991-11-05 1994-03-22 Kiichiro Ozaki 間接的癌治療剤
WO1998056941A1 (en) * 1995-12-12 1998-12-17 Tai Ho Chung Carbohydrate complex extracted from mycobacterium tuberculosis and process for the preparation thereof
US7205404B1 (en) 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
GB0123756D0 (en) * 2001-10-03 2001-11-21 King S College London A novel chaperone-type of adjuvant for vaccination - Basic 1
PT1618128E (pt) * 2003-04-23 2010-10-13 Max Planck Gesellschaft Vacina de tuberculose com eficácia melhorada
US20090208486A1 (en) * 2004-03-09 2009-08-20 Makoto Taketo Pharmaceutical composition comprising cxcr3 inhibitor
US20140199347A1 (en) * 2011-02-10 2014-07-17 University Of Louisville Research Foundation, Inc. Adjuvant compositions with 4-1bbl
JP5999639B2 (ja) * 2011-11-25 2016-09-28 国立研究開発法人産業技術総合研究所 免疫刺激因子担持微粒子
CN105999260B (zh) * 2016-05-13 2019-12-10 四川大学 氢氧化铝凝胶-氯化钠复合免疫佐剂及其制备方法和用途
JP7367906B2 (ja) 2019-04-10 2023-10-24 株式会社 シコク 手摺装置
EP4082577A4 (en) * 2019-12-27 2024-01-03 Zeria Pharmaceutical Co., Ltd. CANCER TREATMENT METHOD AND DRUG

Also Published As

Publication number Publication date
AU2021357131A1 (en) 2023-05-25
AU2021357131A9 (en) 2025-03-13
EP4226939A4 (en) 2024-11-13
CA3194869A1 (en) 2022-04-14
EP4226939A1 (en) 2023-08-16
TW202228739A (zh) 2022-08-01
CN116322771A (zh) 2023-06-23
JPWO2022075458A1 (https=) 2022-04-14
BR112023006220A2 (pt) 2023-05-09
MX2023004103A (es) 2023-04-27
WO2022075458A1 (ja) 2022-04-14
US20230372476A1 (en) 2023-11-23
ZA202304219B (en) 2023-12-20

Similar Documents

Publication Publication Date Title
US11376272B2 (en) Methods of modulating immune activity
Corrales et al. Innate immune signaling and regulation in cancer immunotherapy
WO2021053667A2 (en) Combination cancer therapy and cytokine control therapy for cancer treatment
TWI855989B (zh) 藉由投予抗her3抗體－藥物複合體之egfr－tki抗性之非小細胞肺癌的治療方法
JP2021119145A (ja) 移植片対宿主病を処置し予防する方法
JP2020164539A (ja) 腫瘍免疫寛容を破綻させるためのｙａｐの阻害方法
CN111372584A (zh) Tim-3和pd-1途径的双重抑制剂
JP2021121622A (ja) 組合せおよびその使用および処置
JP2017524737A (ja) 腫瘍微小環境に影響する抗癌剤と組み合わせたβ−グルカン
JP2023509359A (ja) 鉄依存性細胞分解の誘導物質との併用抗癌療法
WO2022265864A9 (en) Tim-3 modulates anti-tumor immunity by regulating inflammasome activation
JP2022512161A (ja) 免疫療法のための組成物及び方法
KR20220116438A (ko) 암 치료를 위한 미생물총 및 대사산물의 힘 활용
US20210379106A1 (en) Oxabicycloheptanes for enhancing car t cell function
WO2019165307A1 (en) Combination cancer therapy with anti-cancer agents and antibodies targeting a complex comprising non-classical hla-i and neoantigen
WO2023172643A1 (en) The combination of macrophage-directed immunotherapy and targeted agents for treatment of cancer
JP7080234B2 (ja) ベンズアミドおよび活性化合物組成物および使用方法
KR20230084177A (ko) 결핵균 추출물의 신규 용도
EP4031655A2 (en) Combination cancer therapy and cytokine control therapy for cancer treatment
WO2017064558A1 (ja) 新規免疫賦活化剤
KR20260018046A (ko) 이전의 면역 관문 억제제 노출 이력이 있는 대상체의 암 치료 방법
JP2024533502A (ja) がんの処置および免疫チェックポイント阻害剤の有効性の増強のための方法および組成物
US20260069705A1 (en) Methods and compositions for enhanced antigen presentation in the tumor microenvironment
RU2783759C2 (ru) Противоопухолевое средство и усилитель противоопухолевого действия
WO2026052715A1 (en) Interleukin-2 variants with modified biological activity

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230411

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241007

Comment text: Request for Examination of Application